BEBT-908 (PI3Kα inhibitor 1) |
| Catalog No.GC33145 |
BEBT-908 (PI3K&alpha ; inhibiteur 1) (PI3Kα ; inhibiteur 1) est un PI3Kα sélectif ; l'inhibiteur extrait du brevet US/20120088764A1, Composé 243, a une IC50<0,1 μM, PI3Kα l'inhibiteur 1 inhibe également l'HDAC (0,1 μM≤IC50≤1 μM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1235449-52-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BEBT-908 is a selective PI3Kα inhibitor extracted from patent US/20120088764A1, Compound 243, has an IC50<0.1 μM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 μM≤IC50≤1 μM) .
[1]. Cai Xiong, et al. Deazapurines, thienopyrimidines and furopyrimidines as phosphoinositide 3-kinase inhibitors with a zinc binding moiety and their preparation and use in the treatment of diseases. From U.S. Pat. Appl. Publ. (2012), US 20120088764 A1 20120412.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *